Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Neumovec: A novel therapy for epilepsy

Reference number
Coordinator CombiGene AB
Funding from Vinnova SEK 500 000
Project duration July 2017 - December 2017
Status Completed

Important results from the project

The aim of the project was to analyze and evaluate the clinical and market feasibility of Neumovec, a novel patented gene therapy for the treatment of epilepsy. During the project, we have also defined all details related to the planned phase I/IIa clinical validation. The set goals were satisfactorily fulfilled.

Expected long term effects

In the project, we have confirmed the clinical and market feasibility of Neumovec as well as defined all details related to the planned phase I/IIa clinical validation. The results of our analyzes and assessments will provide a basis for our strategic decisions related to the development of the therapy.

Approach and implementation

During the course of the project, we have performed an advanced market analysis including, for instance, the competitive landscape, user needs and regulatory aspects. We have also identified potential partners for the planned out-licensing deal and defined the company´s financial expectations connected to it. In addition, we have developed a plan for the following phase I/IIa clinical validation that will be a significant step towards commercialization of the therapy.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 14 June 2019

Reference number 2017-03354

Page statistics